Last updated
Clinical data
AHFS/ Micromedex Detailed Consumer Information
MedlinePlus a601248
ATC code
Pharmacokinetic data
Bioavailability 0.9-1 (oral)
Protein binding 10-20%
Metabolism glucuronidation (primary)
Elimination half-life 9-14 R, 13-20 S
Excretion 30-50% urine (unchanged)
  • N-(2,6-dimethylphenyl)alaninamide
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard 100.050.441 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C11H16N2O
Molar mass 192.262 g·mol−1
3D model (JSmol)
  • O=C(Nc1c(cccc1C)C)C(N)C
  • InChI=1S/C11H16N2O/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12/h4-6,9H,12H2,1-3H3,(H,13,14) Yes check.svgY

Tocainide (Tonocard) is a class Ib antiarrhythmic agent. It is no longer sold in the United States.



Tocainide is a lidocaine analog, that does not have significant 1st pass metabolism. It is found in two enantiomers. The R isomer is 4x as potent as the S. Oral bioavailability is 0.9-1.0. In the blood tocainide is 10-20% protein bound. The Volume of distribution is 2.5-3.5 L/kg. 30-50% is excreted unchanged in the urine. The more active R-isomer is cleared faster in anephric patients or those with severe renal dysfunction. The main metabolite is the glucuronidated tocainide carbamic acid. The glucuronosyl transferase is apparently induced by rifampin. Weak inhibition of Cyp1A2 leads to a mild theophylline interaction. (Not verbatim)


Tocainide synthesis: Tocainide synthesis.png
Tocainide synthesis:

Related Research Articles

<span class="mw-page-title-main">Glutethimide</span> Medication

Glutethimide is a hypnotic sedative that was introduced by Ciba in 1954 as a safe alternative to barbiturates to treat insomnia. Before long, however, it had become clear that glutethimide was just as likely to cause addiction and caused similar withdrawal symptoms. Doriden was the brand-name version. Current production levels in the United States point to its use only in small-scale research. Manufacturing of the drug was discontinued in the US in 1993 and discontinued in several eastern European countries in 2006.

<span class="mw-page-title-main">Carbidopa</span> Chemical compound

Carbidopa (Lodosyn) is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa. This property is significant in that it allows a greater proportion of administered levodopa to cross the blood–brain barrier for central nervous system effect, instead of being peripherally metabolised into substances unable to cross said barrier.

<span class="mw-page-title-main">Isosorbide</span> Chemical compound

Isosorbide is a bicyclic chemical compound from the group of diols and the oxygen-containing heterocycles, containing two fused furan rings. The starting material for isosorbide is D-sorbitol, which is obtained by catalytic hydrogenation of D-glucose, which is in turn produced by hydrolysis of starch. Isosorbide is discussed as a plant-based platform chemical from which biodegradable derivatives of various functionality can be obtained.

<span class="mw-page-title-main">Chloropyramine</span> Chemical compound

Chloropyramine is a classical first-generation antihistamine drug approved in Eastern European countries for the treatment of allergic conjunctivitis, allergic rhinitis, bronchial asthma, and other atopic (allergic) conditions. Related indications for clinical use include angioedema, allergic reactions to insect bites, food and drug allergies, and anaphylactic shock.

<span class="mw-page-title-main">Procyclidine</span> Group of stereoisomers

Procyclidine is an anticholinergic drug principally used for the treatment of drug-induced parkinsonism, akathisia and acute dystonia, Parkinson's disease, and idiopathic or secondary dystonia.

Roger Edward Collingwood Altounyan (1922–1987) was an Anglo-Armenian physician and pharmacologist who pioneered the use of sodium cromoglycate as a remedy for asthma. His family relocated to the United Kingdom where he studied medicine and started his pioneering research.

<span class="mw-page-title-main">Lorcainide</span> Antiarrythmic agent

Lorcainide is a Class 1c antiarrhythmic agent that is used to help restore normal heart rhythm and conduction in patients with premature ventricular contractions, ventricular tachycardiac and Wolff–Parkinson–White syndrome. Lorcainide was developed by Janssen Pharmaceutica (Belgium) in 1968 under the commercial name Remivox and is designated by code numbers R-15889 or Ro 13-1042/001. It has a half-life of 8.9 +- 2.3 hrs which may be prolonged to 66 hrs in people with cardiac disease.

<span class="mw-page-title-main">Mazindol</span> Chemical compound

Mazindol is a stimulant drug which is used as an appetite suppressant. It was developed by Sandoz-Wander in the 1960s.

<span class="mw-page-title-main">Prenalterol</span>

Prenalterol is a cardiac stimulant which acts as a β1 adrenoreceptor agonist.

<span class="mw-page-title-main">Fletazepam</span> Chemical compound

Fletazepam is a drug which is a benzodiazepine derivative. It has sedative and anxiolytic effects similar to those produced by other benzodiazepine derivatives, but is mainly notable for its strong muscle relaxant properties.

<span class="mw-page-title-main">Uldazepam</span> Chemical compound

Uldazepam is a drug which is a benzodiazepine derivative. It has sedative and anxiolytic effects similar to those of other benzodiazepines.

<span class="mw-page-title-main">Etazolate</span> Chemical compound

Etazolate (SQ-20,009, EHT-0202) is an anxiolytic drug which is a pyrazolopyridine derivative and has unique pharmacological properties. It acts as a positive allosteric modulator of the GABAA receptor at the barbiturate binding site, as an adenosine antagonist of the A1 and A2 subtypes, and as a phosphodiesterase inhibitor selective for the PDE4 isoform. It is currently in clinical trials for the treatment of Alzheimer's disease.

<span class="mw-page-title-main">Carbuterol</span> Chemical compound

Carbuterol is a short-acting β2 adrenoreceptor agonist.

<span class="mw-page-title-main">Bacampicillin</span> Chemical compound

Bacampicillin (INN) is a penicillin antibiotic. It is a prodrug of ampicillin with improved oral bioavailability.

<span class="mw-page-title-main">Cartazolate</span> Chemical compound

Cartazolate (SQ-65,396) is a drug of the pyrazolopyridine class. It acts as a GABAA receptor positive allosteric modulator at the barbiturate binding site of the complex and has anxiolytic effects in animals. It is also known to act as an adenosine antagonist at the A1 and A2 subtypes and as a phosphodiesterase inhibitor. Cartazolate was tested in human clinical trials and was found to be efficacious for anxiety but was never marketed. It was developed by a team at E.R. Squibb and Sons in the 1970s.

<span class="mw-page-title-main">Camfetamine</span> Chemical compound

Camfetamine (N-methyl-3-phenyl-norbornan-2-amine) is a stimulant drug closely related to the appetite suppressant fencamfamine, being its N-methyl homologue. It has been sold as a designer drug following the banning of mephedrone and related substituted cathinone derivatives in many countries, and reportedly has slightly stronger stimulant effects than fencamfamine, but with correspondingly more severe side effects.

<span class="mw-page-title-main">Floctafenine</span> Chemical compound

Floctafenine is a nonsteroidal anti-inflammatory drug (NSAID).

<span class="mw-page-title-main">Moxazocine</span> Chemical compound

Moxazocine (BL-4566) is an opioid analgesic of the benzomorphan family which was never marketed. It acts as a partial agonist or mixed agonist/antagonist of the opioid receptors and binds preferentially to the κ-opioid receptor. Despite its failure to reach the market, clinical studies demonstrated moxazocine to be approximately 10x as potent by weight as morphine as an analgesic.

Sulfinalol is a beta adrenergic receptor antagonist.

<span class="mw-page-title-main">3-Dimethylaminoacrolein</span> Chemical compound

3-Dimethylaminoacrolein is an organic compound with the formula Me2NC(H)=CHCHO. It is a pale yellow water-soluble liquid. The compound has a number of useful and unusual properties, e.g. it "causes a reversal of the hypnotic effect of morphine in mice" and has a "stimulating effect in humans".


  1. DE 2235745,Boyes RN, Byrnes EW,"Antiarrhythmisch Wirksame Verbindung, Verfahren zu Deren Herstellung und Deren Verwendung",issued 1972, assigned to Astra Pharmaceutical Products Inc.
  2. GB 1461602,"Primary Amino Acylanilides Methods of Making the Same and Use as Antiarrhythmic Drugs",issued 1974, assigned to Astra Pharmaceutical Products Inc.
  3. DE 2400540,Boyes RN, Duce BR, Smith EM, Byrnes EW,"Primaeraminoacylanilide, Verfahren zu Deren Herstellung und Sie Enthaltende Arzneimittel",issued 1974, assigned to Astra Pharmaceutical Products Inc.
  4. Byrnes EW, McMaster PD, Smith ER, Blair MR, Boyes RN, Duce BR, et al. (October 1979). "New antiarrhythmic agents. 1. Primary alpha-amino anilides". Journal of Medicinal Chemistry. 22 (10): 1171–6. doi:10.1021/jm00196a005. PMID   513064.

Further reading